Vera, BeatrizMartínez Vélez, NaiaraXipell, EnricAcanda de la Rocha, ArletPatiño García, AnaSaez Castresana, JavierGonzalez Huarriz, MarisolCascallò, ManelAlemany Bonastre, RamonAlonso, Marta M.2018-12-112018-12-112016-01-25https://hdl.handle.net/2445/126898Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease. In this study we characterize the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selective oncolytic adenovirus that has proven safe and effective in the treatment of several solid tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro. In vivo, in two different orthotopic glioma models, a single intra-tumoral administration of VCN-01 increased overall survival significantly and led to long-term survivors free of disease.10 p.application/pdfengcc by (c) Vera et al., 2016http://creativecommons.org/licenses/by/3.0/es/GliomaAdenovirusGliomasAdenovirusesinfo:eu-repo/semantics/article2018-07-25info:eu-repo/semantics/openAccess26808201